Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.73 |
| ▸ | RAB9A | P51151 | 12/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.73 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.73 |
| ▸ | RELA | Q04206 | 4/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278505 | 0.84 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1819335 | 0.80 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL3266299 | 0.80 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL5027153 | 0.79 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL5025801 | 0.78 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL8277520 | 0.78 | MAPT (0.57) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL3112891 | 0.78 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL30073965 | 0.78 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL8278396 | 0.77 | TDP1 (0.58) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1856861 | 0.76 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | claimed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | claimed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | claimed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | claimed |
| US-9718784-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717709-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9447058-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | DUKE UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-9315449-B2 | Substituted pyrazoles as heat shock transcription factor activators | DUKE UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-9156775-B2 | Substituted 1,3-thiazoles as heat shock transcription factor 1 activators | DUKE UNIVERSITY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | CHAPERONE THERAPEUTICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | DUKE UNIVERSITY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221958-A1 | SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS | HSF1, HSP90AB1, HSPBP1 | NPC1 3262/4885RAB9A 3776/4885SMN1; SMN2 3676/4885 |
| US-20160024035-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | NPC1 2279/4885RAB9A 3656/4885SMN1; SMN2 2958/4885 |
| US-20110112073-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | NPC1 2279/4885RAB9A 3656/4885SMN1; SMN2 2958/4885 |
| US-20130267543-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | NPC1 2279/4885RAB9A 3656/4885SMN1; SMN2 2958/4885 |
| US-20170000768-A1 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF | HSF1, HSP90AB1, HSPBP1 | NPC1 2279/4885RAB9A 3656/4885SMN1; SMN2 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.